Aeglea BioTherapeutics, Inc. (AGLE): Price and Financial Metrics


Aeglea BioTherapeutics, Inc. (AGLE): $1.22

-0.05 (-3.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AGLE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AGLE POWR Grades

  • Sentiment is the dimension where AGLE ranks best; there it ranks ahead of 98.14% of US stocks.
  • AGLE's strongest trending metric is Momentum; it's been moving up over the last 179 days.
  • AGLE ranks lowest in Stability; there it ranks in the 8th percentile.

AGLE Stock Summary

  • With a price/sales ratio of 13.46, AEGLEA BIOTHERAPEUTICS INC has a higher such ratio than 92.06% of stocks in our set.
  • As for revenue growth, note that AGLE's revenue has grown -61.54% over the past 12 months; that beats the revenue growth of just 3.01% of US companies in our set.
  • In terms of volatility of its share price, AGLE is more volatile than 96.88% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AEGLEA BIOTHERAPEUTICS INC are GLYC, VSTM, CRBU, TGTX, and PRTC.
  • Visit AGLE's SEC page to see the company's official filings. To visit the company's web site, go to www.aegleabio.com.

AGLE Valuation Summary

  • In comparison to the median Healthcare stock, AGLE's price/earnings ratio is 103.88% lower, now standing at -0.9.
  • Over the past 81 months, AGLE's price/earnings ratio has gone up 8.8.

Below are key valuation metrics over time for AGLE.

Stock Date P/S P/B P/E EV/EBIT
AGLE 2022-11-25 13.1 1.1 -0.9 -0.5
AGLE 2022-11-23 12.8 1.1 -0.9 -0.5
AGLE 2022-11-22 12.9 1.1 -0.9 -0.5
AGLE 2022-11-21 13.4 1.1 -0.9 -0.5
AGLE 2022-11-18 12.8 1.1 -0.9 -0.5
AGLE 2022-11-17 12.6 1.1 -0.9 -0.4

AGLE Growth Metrics

    Its 2 year cash and equivalents growth rate is now at 16.82%.
  • Its 4 year price growth rate is now at 7.51%.
  • The year over year net income to common stockholders growth rate now stands at 10.41%.
Over the past 70 months, AGLE's revenue has gone up $1,177,000.

The table below shows AGLE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 5.805 -81.272 -85.439
2022-06-30 7.03 -83.204 -87.512
2022-03-31 20.101 -60.449 -72.019
2021-12-31 18.739 -53.716 -65.801
2021-09-30 15.095 -51.58 -68.069
2021-06-30 13.696 -52.116 -65.795

AGLE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AGLE has a Quality Grade of D, ranking ahead of 14.56% of graded US stocks.
  • AGLE's asset turnover comes in at 0.087 -- ranking 276th of 681 Pharmaceutical Products stocks.
  • REGN, MNKD, and JAZZ are the stocks whose asset turnover ratios are most correlated with AGLE.

The table below shows AGLE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.087 1 -0.879
2021-03-31 0.000 NA -1.076
2020-12-31 0.000 NA -1.144
2020-09-30 0.000 NA -1.166
2020-06-30 0.000 NA -1.351
2020-03-31 0.000 NA -1.363

AGLE Price Target

For more insight on analysts targets of AGLE, see our AGLE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.50 Average Broker Recommendation 1.56 (Moderate Buy)

AGLE Stock Price Chart Interactive Chart >

Price chart for AGLE

AGLE Price/Volume Stats

Current price $1.22 52-week high $6.57
Prev. close $1.27 52-week low $0.37
Day low $1.22 Volume 150,200
Day high $1.27 Avg. volume 1,243,370
50-day MA $0.82 Dividend yield N/A
200-day MA $1.20 Market Cap 75.04M

Aeglea BioTherapeutics, Inc. (AGLE) Company Bio


Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. The company was founded in 2013 and is based in Austin, Texas.


AGLE Latest News Stream


Event/Time News Detail
Loading, please wait...

AGLE Latest Social Stream


Loading social stream, please wait...

View Full AGLE Social Stream

Latest AGLE News From Around the Web

Below are the latest news stories about AEGLEA BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate AGLE as an investment opportunity.

Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been appointed chief medical officer. Dr. Neuman's appointment is an internal promotion from her previous role as Aeglea's senior vice president of clinical development.

Yahoo | November 15, 2022

JonesTrading Keeps Their Buy Rating on Aeglea Biotherapeutics (AGLE)

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Aeglea Biotherapeutics (AGLE - Research Report), with a price target of $3.00. The company's shares opened today at $1.20.According to TipRanks, Roy is a 4-star analyst with an average return of 7.9% and a 32.66% success rate. Roy covers the Healthcare sector, focusing on stocks such as Curis, Aeglea Biotherapeutics, and AVEO Pharma.In addition to JonesTrading, Aeglea Biotherapeutics also received a Buy from Wells Fargo's Yanan Zhu in a report issued on October 28. However, on the same day, H.C. Wainwright reiterated a Hold rating on Aeglea Biotherapeutics (NASDAQ: AGLE).

Ryan Adist on TipRanks | November 3, 2022

Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 3, 2022

Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2022 and provided program updates.

Yahoo | November 3, 2022

Analysts Offer Insights on Healthcare Companies: Seagen (SGEN), Aeglea Biotherapeutics (AGLE) and Argenx Se (ARGX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Seagen (SGEN – Research Report), Aeglea Biotherapeutics (AGLE – Research Report) and Argenx Se (ARGX – Research Report). Seagen (SGEN) Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on Seagen today and set a price target of $183.00. The company's shares closed last Thursday at $131.25. According to TipRanks.com, Shu is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -25.2% and a 23.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

Howard Kim on TipRanks | October 28, 2022

Read More 'AGLE' Stories Here

AGLE Price Returns

1-mo 18.45%
3-mo 129.45%
6-mo 95.48%
1-year -80.45%
3-year -85.73%
5-year -74.21%
YTD -74.32%
2021 -39.64%
2020 3.01%
2019 2.00%
2018 38.45%
2017 24.37%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.1509 seconds.